FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells

Biochemical and Biophysical Research Communications

Volumn 458, Issue 2, 2015, Pages 334-340

  Schuster, Susanne ^a   Penke, Melanie ^a   Gorski, Theresa ^a   Gebhardt, Rolf ^b   Weiss, Thomas S ^c   Kiess, Wieland ^a   Garten, Antje ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

AMPK; FK866; Hepatocarcinoma cells; mTOR; NAD; NAMPT

Indexed keywords

ADENOSINE TRIPHOSPHATE; DAPORINAD; DIMETHYL SULFOXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; LYSINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; S6 KINASE; ACRYLAMIDE DERIVATIVE; CYTOKINE; MTOR PROTEIN, HUMAN; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; PIPERIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ACETYLATION; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DEATH; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MAMMALIA;

ACRYLAMIDES; ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84923306335     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.111     Document Type: Article

References (37)

1. A. Chiarugi, C. Dolle, and R. Felici, et al. The NAD metabolome-a key determinant of cancer cell biology Nat. Rev. Cancer 12 2012 741 752
2. J.R. Revollo, A.A. Grimm, and S. Imai The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals Curr. Opin. Gastroenterol. 23 2007 164 170
3. C. Dolle, R.H. Skoge, and M.R. Vanlinden, et al. NAD biosynthesis in humans-enzymes, metabolites and therapeutic aspects Curr. Top. Med. Chem. 13 2013 2907 2917
4. M. Rechsteiner, D. Hillyard, and B.M. Olivera Magnitude and significance of NAD turnover in human cell line D98/AH2 Nature 259 1976 695 696
5. T.Q. Bi, and X.M. Che Nampt/PBEF/visfatin and cancer Cancer Biol. Ther. 10 2010 119 125
6. B.K. Thakur, T. Dittrich, and P. Chandra, et al. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells Int. J. Cancer 132 2013 766 774
7. M. Cea, A. Cagnetta, and M. Fulciniti, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition Blood 120 2012 3519 3529
8. A. Garten, S. Petzold, and A. Barnikol-Oettler, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes Biochem. Biophys. Res. Commun. 391 2010 376 381
9. S. Schuster, M. Penke, and T. Gorski, et al. Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes PLoS One 9 2014 e91045
10. B. Stewart, and C.P. Wild World Cancer Report 2014 2014 WHO Press
11. J.M. Llovet, S. Ricci, and V. Mazzaferro, et al. Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
12. M. Hasmann, and I. Schemainda FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis Cancer Res. 63 2003 7436 7442
13. J.A. Khan, X. Tao, and L. Tong Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents Nat. Struct. Mol. Biol. 13 2006 582 588
14. I. Gehrke, E.D. Bouchard, and S. Beiggi, et al. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells Clin. Cancer Res. 20 2014 4861 4872
15. A. Nahimana, A. Attinger, and D. Aubry, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies Blood 113 2009 3276 3286
16. T.Q. Bi, X.M. Che, and X.H. Liao, et al. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil Oncol. Rep. 26 2011 1251 1257
17. B. Tan, D.A. Young, and Z.H. Lu, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications J. Biol. Chem. 288 2013 3500 3511
18. M. Muruganandham, A.A. Alfieri, and C. Matei, et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy Clin. Cancer Res. 11 2005 3503 3513
19. M.K. Christensen, K.D. Erichsen, and U.H. Olesen, et al. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship J. Med. Chem. 56 2013 9071 9088
20. J. Cheng, T. Huang, and Y. Li, et al. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma PLoS One 9 2014 e93256
21. B. Faubert, G. Boily, and S. Izreig, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo Cell. Metab. 17 2013 113 124
22. L. Zheng, W. Yang, and F. Wu, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma Clin. Cancer Res. 19 2013 5372 5380
23. D.R. Bolster, S.J. Crozier, and S.R. Kimball, et al. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling J. Biol. Chem. 277 2002 23977 23980
24. D.G. Hardie The AMP-activated protein kinase pathway-new players upstream and downstream J. Cell. Sci. 117 2004 5479 5487
25. L. Zhou, Y. Huang, and J. Li, et al. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma Med. Oncol. 27 2010 255 261
26. R.E. Ashworth, and J. Wu Mammalian target of rapamycin inhibition in hepatocellular carcinoma World J. Hepatol. 6 2014 776 782
27. F. Chiarini, C. Evangelisti, and J.A. McCubrey, et al. Current treatment strategies for inhibiting mTOR in cancer Trends Pharmacol. Sci. 36 2 2015 124 135
28. T.S. Weiss, S. Pahernik, and I. Scheruebl, et al. Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid J. Hepatol. 38 2003 476 482
29. G.C. Elliott, J. Ajioka, and C.Y. Okada A rapid procedure for assaying nicotinamide phosphoribosyltransferase Anal. Biochem. 107 1980 199 205
30. W. Xu, Y. Li, and C. Liu, et al. Protein lysine acetylation guards metabolic homeostasis to fight against cancer Oncogene 33 2014 2279 2285
31. A. Villanueva, D.Y. Chiang, and P. Newell, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
32. J. Sinnett-Smith, K. Kisfalvi, and R. Kui, et al. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK Biochem. Biophys. Res. Commun. 430 2013 352 357
33. J. Woodard, and L.C. Platanias AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival Biochem. Biophys. Res. Commun. 398 2010 135 139
34. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
35. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat. Rev. Cancer 6 2006 729 734
36. S.M. Hadad, L. Baker, and P.R. Quinlan, et al. Histological evaluation of AMPK signalling in primary breast cancer BMC Cancer 9 2009 307
37. P. Wang, T.Y. Xu, and Y.F. Guan, et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway Ann. Neurol. 69 2011 360 374.